Response of BRCA1-mutated gallbladder cancer to olaparib: A case report

被引：3

作者：

Yuan Xie ^{[1
]}

Yan Jiang ^{[2
]}

Xiao-bo Yang ^{[1
]}

An-qiang Wang ^{[1
]}

Yong-chang Zheng ^{[1
]}

Xue-shuai Wan ^{[1
]}

Xin-ting sang ^{[1
]}

Kai Wang ^{[3
]}

Da-Dong Zhang ^{[2
]}

Jia-Jia Xu ^{[2
]}

Fu-gen Li ^{[2
]}

Hai-tao Zhao ^{[1
]}

机构：

[1] Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

[2] Institute of Precision Medicine, 3D Medicines Inc 3. Center for Precision Medicine, Zhejiang University International Hospital

来源：

World Journal of Gastroenterology | 2016年 / 46期

关键词：

BRCA; Mutation; Olaparib; Poly ADP-ribose polymerase inhibitor; gallbladder cancer;

D O I：

暂无

中图分类号：

R735.8 [胆囊、胆道肿瘤];

学科分类号：

100214 ;

摘要：

gallbladder cancer(gbc), although considered as a relatively rare malignancy, is the most common neoplasm of the biliary tract system. the late diagnosis and abysmal prognosis present challenges to treatment. the overall 5-year survival rate for metastatic gbc patients is extremely low. BRC A1 and BRCA2 are the breast cancer susceptibility genes and their mutation carriers are at a high risk for cancer development, both in men and women. Olaparib, an oral poly ADP-ribose polymerase inhibitor, has been approved by the Food and Drug Administration and the European commission for the treatment of ovarian cancer with any BRCA1/2 mutations. the first case of BRCA1-mutated gbc patient who responded to olaparib treatment is reported here.

引用

收藏

页码：10254 / 10259

页数：6

相关论文

共 50 条

[31] Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report [J].

Wu, Chao ;

Fan, Mengjiao ;

Hu, Yi .

ANTI-CANCER DRUGS, 2022, 33 (01) :E734-E737

[32] Increasing radiosensitivity by the combined inhibition of PARP1 and PI3K in BRCA1-mutated triple negative breast cancer [J].

Zhou, J. ;

Tang, L. Y. ;

Zhang, X. H. ;

Wang, J. ;

Yang, L. C. ;

Wu, S. G. .

INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2020, 18 (02) :283-293

[33] Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report [J].

Smith, Jarrod T. ;

Sama, Shashank ;

Florou, Vaia ;

Nevala-Plagemann, Christopher ;

Garrido-Laguna, Ignacio .

JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) :2637-2643

[34] PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice [J].

Bosnjak, Masa ;

Jesenko, Tanja ;

Markelc, Bostjan ;

Janzic, Larisa ;

Cemazar, Maja ;

Sersa, Gregor .

BIOELECTROCHEMISTRY, 2021, 140

[35] Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy [J].

Lorusso, Domenica ;

Tripodi, Elisa ;

Maltese, Giuseppa ;

Lepori, Stefano ;

Sabatucci, Ilaria ;

Bogani, Giorgio ;

Raspagliesi, Francesco .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 :1501-1509

[36] Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation [J].

Stewart, James ;

George, Angela ;

Banerjee, Susana .

EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (10) :947-958

[37] ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination [J].

Li, Huan ;

Chatla, Srinivas ;

Liu, Xiaolei ;

Tian, Zhen ;

Vekariya, Umeshkumar ;

Wang, Peng ;

Kim, Dongwook ;

Octaviani, Stacia ;

Lian, Zhaorui ;

Morton, George ;

Feng, Zijie ;

Yang, Dan ;

Sullivan-Reed, Katherine ;

Childers, Wayne ;

Yu, Xiang ;

Chitrala, Kumaraswamy Naidu ;

Madzo, Jozef ;

Skorski, Tomasz ;

Huang, Jian .

CANCER LETTERS, 2025, 613

[38] An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer [J].

Prete, Alessandra Anna ;

Procaccio, Letizia ;

Bergamo, Francesca ;

Rasola, Cosimo ;

Nappo, Floriana ;

Zagonel, Vittorina ;

Lonardi, Sara .

CURRENT ONCOLOGY, 2022, 29 (02) :544-550

[39] Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report [J].

Jin, Chang'e ;

He, Zhengqiang ;

Guo, Min ;

Liu, Shengguo ;

Wang, Yan ;

Qiu, Jinfan ;

Li, Chenhui ;

Wu, Di .

ANTI-CANCER DRUGS, 2022, 33 (07) :696-700

[40] Development of Erythema Nodosum After Olaparib Treatment in a Patient With Recurrent Breast Cancer and BRCA2 Mutation: A Case Report [J].

Saito, Masayuki ;

Fujii, Kimihito ;

Banno, Hirona ;

Ito, Yukie ;

Nakano, Shogo .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)

← 1 2 3 4 5 →